The global cancer screening market is expected to grow at a CAGR of 6.00% during the forecast period of 2025-2034, driven by continuous advancements in cancer screening technologies and rising cancer incidence across the globe.
Base Year
Historical Year
Forecast Year
The integration of AI-powered diagnostics, liquid biopsies, and advanced imaging techniques is revolutionizing cancer screening. These innovations enhance detection accuracy, reduce false positives, and improve accessibility, making early diagnosis more efficient.
In May 2024, Quest Diagnostics acquired PathAI Diagnostics to advance AI-driven cancer screening solutions. This collaboration aimed to improve diagnostic speed and accuracy, leveraging digital pathology for efficient cancer detection. Such strategic moves are enhancing innovation, strengthening the market landscape, and expanding access to high-quality screening technologies.
North America will likely lead the market due to a strong healthcare infrastructure, high awareness levels, and extensive government-led early detection programs.
Cancer screening plays a crucial role in early disease detection, enabling timely treatment and improving survival rates. The rising prevalence of various cancers, including breast, cervical, and lung cancer, has intensified the demand for effective screening methods. Advancements in AI-powered diagnostics, liquid biopsies, and imaging technologies are enhancing detection accuracy and accessibility. Additionally, government initiatives promoting awareness and preventive healthcare are further driving adoption. As early diagnosis remains a priority in oncology care, the market is poised for sustained growth, shaping the future of healthcare by enabling improved patient outcomes.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Prevalence of Cancer
The global rise in various cancer types, such as cervical, breast, and colorectal cancer, is amplifying the need for early detection to initiate timely treatment and improve survival rates. Regular screening is becoming essential to identify cancers at an early stage, reducing mortality and enhancing patient outcomes. According to the American Cancer Society, in 2025, approximately 13,360 new cases of invasive cervical cancer are expected to be diagnosed in the United States, with about 4,320 women predicted to die from the disease. This growing burden is driving the demand for advanced screening, and diagnostics, boosting the market for innovative technologies and awareness campaigns to improve early detection and patient outcomes.
Technological Advancements to Drive Cancer Screening Market Value
Innovations in diagnostic technologies, including such as liquid-based cytology, advanced imaging techniques, and AI-powered tools, are revolutionizing cancer screening. These advancements offer faster results, improved precision, and enhanced patient outcomes, addressing critical needs in managing various cancer types. The integration of digital health platforms further drives efficiency in screening programs, making them more efficient and accessible. With increasing awareness and adoption of these cutting-edge solutions, the market is poised for significant growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer Screening Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Market Segmentation by Application is Projected to Hold a Substantial Market Share
Based on application, the market is divided into breast cancer, colorectal cancer, lung cancer, prostate cancer, cervical cancer, and others. Among these, breast cancer is expected to lead the market due to its high prevalence. As per the American Cancer Society, in 2024, an estimated 310,720 women were diagnosed with breast cancer in the United States, further reinforcing the importance of early screening. Increased awareness from campaigns and strong guidelines recommending regular screenings are further boosting demand.
Cancer Screening Market Segmentation by End User to Witness Significant Growth
Based on the end user, the market is segmented into hospitals, specialty clinics, diagnostic labs, cancer institutes, and others. Among these, hospitals are expected to lead the market share due to their comprehensive resources, access to advanced technologies, and ability to offer a wide range of diagnostic and treatment services all in one place. Being the primary healthcare providers, hospitals are often the first point of contact for patients seeking cancer screenings, and they are equipped with the necessary facilities and specialists, including oncologists and radiologists. As the demand for cancer screenings continues to grow, driven by rising awareness, early detection initiatives, and increasing cancer incidence rates, hospitals are positioning themselves to expand their screening programs. Further, the investments in advanced screening technologies and focus on improving patient access in hospitals will likely drive the market value of this segment in the forecast period.
Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among these, North America is expected to dominate the market due to several factors, including a high prevalence rate of cancer, advanced healthcare infrastructure, and strong government initiatives aimed at promoting early detection and screening. The region has one of the highest rates of cancer diagnosis, which drives demand for screening services. Additionally, the presence of numerous leading healthcare facilities and diagnostic laboratories, along with significant investments in research and development for innovative screening technologies, enhance access to and quality of cancer screening. Moreover, several organizations actively promote screening programs, further increasing participation rates. Overall, the focus on quality healthcare delivery, coupled with ongoing advancements, positions it as a significant driver of growth in the market during the forecast period.
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
The company established in 2000 and headquartered in Saluggia, Italy, is a global leader in immunodiagnostics and molecular diagnostics. The company specializes in developing innovative solutions for infectious diseases, oncology, and genetic disorders. In cancer screening, DiaSorin offers the LIAISON® chemiluminescence immunoassay analyzers and Simplexa™ molecular diagnostic tests, enabling early detection and monitoring of cancer biomarkers. These products provide high sensitivity and specificity, supporting oncologists in making informed clinical decisions, improving patient outcomes, and advancing precision medicine.
Biodesix founded in 2005 and headquartered in Boulder, Colorado, focuses on lung cancer diagnostics through innovative blood-based tests. The company's Nodify XL2® and Nodify CDT® tests help assess the risk of malignancy in pulmonary nodules, enabling early cancer detection. Additionally, VeriStrat®, a proteomic test, provides prognostic insights for advanced non-small cell lung cancer (NSCLC). Biodesix leverages machine learning and genomics to enhance cancer screening accuracy, supporting precision medicine and improving treatment pathways for lung cancer patients.
MedGenome Labs, established in 2013 and headquartered in Foster City, California, is a leading genomics and molecular diagnostics company specializing in oncology. The company offers OncoTrack, a comprehensive cancer gene panel that identifies somatic mutations for early cancer detection and treatment selection. MedGenome utilizes next-generation sequencing (NGS) and liquid biopsy techniques to analyze tumor genetics, enabling personalized therapy recommendations. Their innovative approach enhances cancer screening by improving diagnostic accuracy, supporting oncologists with actionable insights, and advancing precision oncology in global healthcare.
The company established in 2000 and headquartered in Rockville, Maryland, develops AI-driven diagnostic solutions for early cancer detection. Their flagship product, OneTest, is a multi-cancer screening blood test that detects biomarkers associated with lung, liver, pancreatic, and other cancers. OneTest combines machine learning with traditional tumor markers to improve early diagnosis and risk assessment. By offering affordable and accessible screening, 20/20 GeneSystems aims to enhance early cancer detection, reduce mortality rates, and support preventive healthcare initiatives worldwide.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Abbott, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., GE Healthcare, Koninklijke Philips N.V., and QIAGEN.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share